VOLITIONRX LTD
Volition is a multinational epigenetics company developing blood tests to help detect and monitor diseases in humans and animals, including certain cancers and diseases associated with NETosis, such as sepsis. Its technologies analyze circulating nucleosomes and transcription factors, and its tests are designed for laboratory and point-of-care workflows. Its main product areas are Nu.Q® Vet for companion animals, Nu.Q® NETs for NETosis-related diseases, Nu.Q® Discover for nucleosome profiling, and Nu.Q® Cancer for cancer screening and monitoring. Capture-PCR™ and Capture-Seq™ isolate tumor-associated DNA fragments from blood for cancer detection. Volition makes money through licensing and distribution agreements, upfront and milestone payments, royalties, and sales of test kits and key components. It also offers Nu.Q® Discover research services and develops components and ELISA kits at its manufacturing facility in Belgium. The Nu.Q® Vet Cancer Test is commercially available in dogs and is offered through distributors in over twenty countries. Volition is headquartered in Henderson, Nevada.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
No SEC Form 4 filings for $VNRX in the last 30 days.
See all $VNRX insider activity →VolitionRx (NYSE: VNRX) reported Q3 2026 revenue of $1.6M, up 157% YoY, and reduced operating loss by 35% to $3.3M. The company highlighted progress in commercializing its Nu.Q® platform, including partnerships and clinical advancements in sepsis and cancer detection. A conference call is scheduled for November 13 to discuss results.
VolitionRx CEO Cameron Reynolds agreed to a temporary salary reduction from $355,456 to $236,970.50 starting November 1, 2026, as part of company cost-reduction efforts. The reduction continues until the Compensation Committee decides otherwise, according to an SEC filing.
VOLITIONRX LTD (VNRX) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On November 10, 2026, Singapore Volition Pte. Limited (“Singapore Volition”), a wholly-owned subsidiary of VolitionRx Limit
Over the past 7 days, AlphAI's AI scored 5 news stories mentioning VNRX (VOLITIONRX LTD). Coverage has skewed bullish: 1 bullish, 4 neutral, and 0 bearish.
Recent VNRX coverage spans corporate actions, financial news and earnings.
Loss narrowing and cash buildup may support modest upside, but small‑cap volatility limits move size.
The salary reduction signals tighter cost controls but does not affect cash flow directly.
The salary cut may signal cost‑saving pressure but has limited immediate price impact.
Debt reduction improves balance sheet and may lift the stock modestly.
VolitionRx (VNRX) signed a non-binding LOI with Missionpharma to develop, manufacture, and distribute a lateral flow test for NETosis, targeting decentralized use. The test aims at applications in low- and middle-income countries and neonatal sepsis triage.
AlphAI scores every news story that mentions VNRX with an AI model for sentiment and relevance, and aggregates insider trades from VOLITIONRX LTD's SEC EDGAR Form 4 filings. Figures refresh continuously.
VolitionRx (NYSE: VNRX) reported Q3 2026 revenue of $1.6M, up 157% YoY, and reduced operating loss by 35% to $3.3M. The company highlighted progress in commercializing its Nu.Q® platform, including partnerships and clinical advancements in sepsis and cancer detection. A conference call is scheduled for November 13 to discuss results.
VolitionRx CEO Cameron Reynolds agreed to a temporary salary reduction from $355,456 to $236,970.50 starting November 1, 2026, as part of company cost-reduction efforts. The reduction continues until the Compensation Committee decides otherwise, according to an SEC filing.
VOLITIONRX LTD (VNRX) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On November 10, 2026, Singapore Volition Pte. Limited (“Singapore Volition”), a wholly-owned subsidiary of VolitionRx Limit
VOLITIONRX LTD (VNRX) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. EXHIBIT 99.1 VolitionRx Limited Announces $500,000 Partial Pre-Payment of Convertible Note in Cash · Reduces outstanding principal to only $0.7 million on the $2.4 million note and brings total debt reduction across both notes to over $5.0 million since June 30, 2026. · Secures a
VolitionRx (VNRX) signed a non-binding LOI with Missionpharma to develop, manufacture, and distribute a lateral flow test for NETosis, targeting decentralized use. The test aims at applications in low- and middle-income countries and neonatal sepsis triage.
VolitionRx (VNRX) prepaid $500,000 on a $2.4M convertible note to Lind Global, reducing its balance to $706,667. Lind agreed to pause conversion rights until 2027. The company has cut total debt by over $5M since June 30, 2026, including fully satisfying a $7.5M note in September. VolitionRx develops blood tests for disease detection.
VolitionRx reduced its debt by $500,000 in cash, bringing total debt reduction to over $2.4 million since June 30, 2026. The company also secured an agreement to pause conversion rights until January 2027 and defer remaining 2026 repayments. According to the CEO, this prepayment was made ahead of schedule.
VolitionRx's COO, Gaetan Michel, disposed of 608 shares of common stock (VNRX) on September 28, 2026, at $0.2529 per share for tax purposes, leaving 12,232 shares owned.
VOLITIONRX LTD (VNRX) filed an SEC Form 8-K — Unregistered Sales of Equity Securities. Item 3.02 Unregistered Sales of Equity Securities Conversions of Note As previously reported, pursuant to that certain securities purchase agreement dated May 15, 2025 (as amended and restated on January 7, 2026, the “SPA”), VolitionRx Limited (the “Company”) issued to Lind Globa
VolitionRx (VNRX) joins the €6.3M DETECSEPS Consortium in France to evaluate its Nu.Q® NETs assay for early sepsis detection. The project, funded by the French government, aims to improve patient outcomes and reduce healthcare burden. Volition provides the biomarker, while IDS France supplies the analyzer. Sepsis causes 21M deaths annually, with early detection crucial for treatment.
